Taro Pharmaceutical ends licensing agreement with NovaBiotics over Novexatin failure
Taro Pharmaceutical Industries has terminated its licensing agreement with Scottish biotech company NovaBiotics concerning the Novexatin drug after disappointing clinical trial results. The decision follows the failure of Novexatin to achieve its primary endpoint in a Phase 2b study, where it did not demonstrate superiority over a placebo. In May, the Phase 2b trial of […]